Want to see HK:0775 full AI Analyst Report?
0775 Stock Chart & Stats
HK$0.83
>-HK$0.01(-1.22%)
At close: 4:00 PM EST
HK$0.83
>-HK$0.01(-1.22%)
Day’s Range― - ―
52-Week RangeHK$0.55 - HK$1.08
Previous CloseN/A
Volume680.00K
Average Volume (3M)7.56M
Market Cap
HK$5.38B
Enterprise ValueHK$12.46B
Total Cash (Recent Filing)HK$603.07M
Total Debt (Recent Filing)HK$6.62B
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Aug 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding9,611,072,000
10 Day Avg. Volume13,068,694
30 Day Avg. Volume7,559,299
Financial Highlights & Ratios
PEG Ratio-0.90
Price to Book (P/B)2.09
Price to Sales (P/S)1.46
P/FCF Ratio-28.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Diversified Agri/biotech Business ModelAn integrated model combining in-house R&D, manufacturing and multiple-market subsidiaries supports sustained product development, faster commercialization and geographic risk diversification. This structural setup underpins durable revenue levers and long-term pipeline value despite short-term earnings volatility.
Meaningful Equity Capital BufferA tangible equity base (~HK$3.8B) provides a solvency buffer to absorb losses and finance operations or R&D in the medium term. Even with higher leverage, meaningful equity reduces immediate insolvency risk and preserves strategic optionality for restructuring or targeted investments.
Prior Consistent Operating Cash GenerationA history of positive operating cash flow through 2024 indicates the core business was previously cash-generative, suggesting operational cash conversion can recover. This prior track record supports the view that temporary disruption rather than structural failure may explain the 2025 cash decline.
Bears Say
Sharp Margin Compression And Loss-makingA dramatic drop in gross margin and a shift to operating losses indicate structural pressure on pricing, costs or product mix. Persistently lower margins will erode the company’s ability to fund R&D and commercialization internally, making recovery and profitable growth materially harder.
Deteriorated Cash Flow And Large FCF OutflowNegative operating cash flow and a sizable free-cash-flow deficit increase reliance on external financing and constrain reinvestment. Over the medium term this raises refinancing and liquidity risk, especially if margins remain depressed and working capital demands persist.
Elevated And Rising LeverageHigh and rising debt-to-equity amplifies downside risk from earnings weakness by increasing interest burden and reducing financial flexibility. Elevated leverage limits strategic choices, hampers ability to fund R&D internally and increases vulnerability if cash generation does not rebound reliably.
CK Life Sciences International (Holdings), Inc. News
0775 FAQ
What was CK Life Sciences International (Holdings), Inc.’s price range in the past 12 months?
CK Life Sciences International (Holdings), Inc. lowest stock price was HK$0.55 and its highest was HK$1.08 in the past 12 months.
What is CK Life Sciences International (Holdings), Inc.’s market cap?
CK Life Sciences International (Holdings), Inc.’s market cap is HK$5.38B.
When is CK Life Sciences International (Holdings), Inc.’s upcoming earnings report date?
CK Life Sciences International (Holdings), Inc.’s upcoming earnings report date is Aug 11, 2026 which is in 6 days.
How were CK Life Sciences International (Holdings), Inc.’s earnings last quarter?
CK Life Sciences International (Holdings), Inc. released its earnings results on Mar 17, 2026. The company reported -HK$0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.004.
Is CK Life Sciences International (Holdings), Inc. overvalued?
According to Wall Street analysts CK Life Sciences International (Holdings), Inc.’s price is currently Overvalued.
Does CK Life Sciences International (Holdings), Inc. pay dividends?
CK Life Sciences International (Holdings), Inc. pays a Annually dividend of HK$0.008 which represents an annual dividend yield of N/A. See more information on CK Life Sciences International (Holdings), Inc. dividends here
What is CK Life Sciences International (Holdings), Inc.’s EPS estimate?
CK Life Sciences International (Holdings), Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CK Life Sciences International (Holdings), Inc. have?
CK Life Sciences International (Holdings), Inc. has 9,611,072,000 shares outstanding.
What happened to CK Life Sciences International (Holdings), Inc.’s price movement after its last earnings report?
CK Life Sciences International (Holdings), Inc. reported an EPS of -HK$0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of CK Life Sciences International (Holdings), Inc.?
Currently, no hedge funds are holding shares in HK:0775
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CK Life Sciences International (Holdings), Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
89.36%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
9.71%
Trailing 12-Months
Company Description
CK Life Sciences International (Holdings), Inc.
CK Life Sciences International (Holdings), Inc. operates as an investment company, which engages in the business of research and development, manufacturing, commercialization, marketing and selling of products and assets in nutraceuticals, pharmaceuticals and agriculture related business. It operates through the following segments: Agriculture-Related and Health. The company was founded on August 10, 2001 and is headquartered in Hong Kong.
CK Life Sciences International (Holdings), Inc. (0775) Earnings & Revenues
Technical Analysis
Sino Biopharmaceutical
―
Ascletis Pharma, Inc.
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Simcere Pharmaceutical Group Limited
―
Shanghai Henlius Biotech, Inc. Class H
―